These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 9625114)

  • 1. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
    Ouatu-Lascar R; Triadafilopoulos G
    Am J Gastroenterol; 1998 May; 93(5):711-6. PubMed ID: 9625114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus.
    Katzka DA; Castell DO
    Am J Gastroenterol; 1994 Jul; 89(7):989-91. PubMed ID: 8017396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
    Sharma P; Sampliner RE; Camargo E
    Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD).
    Milkes D; Gerson LB; Triadafilopoulos G
    Am J Gastroenterol; 2004 Jun; 99(6):991-6. PubMed ID: 15180715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
    Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
    Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus.
    Loughney T; Maydonovitch CL; Wong RK
    Am J Gastroenterol; 1998 Jun; 93(6):916-9. PubMed ID: 9647018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
    Todd JA; Basu KK; de Caestecker JS
    Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between rate of change in acid exposure along the esophagus and length of Barrett's epithelium.
    Tharalson EF; Martinez SD; Garewal HS; Sampliner RE; Cui H; Pulliam G; Fass R
    Am J Gastroenterol; 2002 Apr; 97(4):851-6. PubMed ID: 12003418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present.
    Singh P; Taylor RH; Colin-Jones DG
    Am J Gastroenterol; 1994 Mar; 89(3):349-56. PubMed ID: 8122643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus.
    Triadafilopoulos G; Kaczynska M; Iwane M
    Am J Gastroenterol; 1996 Jan; 91(1):65-74. PubMed ID: 8561146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis?
    Coenraad M; Masclee AA; Straathof JW; Ganesh S; Griffioen G; Lamers CB
    Am J Gastroenterol; 1998 Jul; 93(7):1068-72. PubMed ID: 9672332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional foregut abnormalities in Barrett's esophagus.
    Stein HJ; Hoeft S; DeMeester TR
    J Thorac Cardiovasc Surg; 1993 Jan; 105(1):107-11. PubMed ID: 8419690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia.
    Csendes A; Smok G; Quiroz J; Burdiles P; Rojas J; Castro C; Henríquez A
    Am J Gastroenterol; 2002 Mar; 97(3):554-60. PubMed ID: 11922546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression.
    Kahaleh M; Van Laethem JL; Nagy N; Cremer M; Devière J
    Endoscopy; 2002 Dec; 34(12):950-5. PubMed ID: 12471537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptoms, acid exposure and motility in patients with Barrett's esophagus.
    Brandt MG; Darling GE; Miller L
    Can J Surg; 2004 Feb; 47(1):47-51. PubMed ID: 14997925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barrett's esophagus in females: a comparative analysis of risk factors in females and males.
    Banki F; Demeester SR; Mason RJ; Campos G; Hagen JA; Peters JH; Bremner CG; Demeester TR
    Am J Gastroenterol; 2005 Mar; 100(3):560-7. PubMed ID: 15743352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression.
    Ouatu-Lascar R; Fitzgerald RC; Triadafilopoulos G
    Gastroenterology; 1999 Aug; 117(2):327-35. PubMed ID: 10419913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
    Menges M; Müller M; Zeitz M
    Am J Gastroenterol; 2001 Feb; 96(2):331-7. PubMed ID: 11232672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus.
    Fiorucci S; Santucci L; Farroni F; Pelli MA; Morelli A
    Am J Gastroenterol; 1989 Oct; 84(10):1263-7. PubMed ID: 2801676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.